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Background : Increased glucose uptake, a process that is mediated by glucose transporter
(Glut1) proteins, is an important metabolic feature in a variety of cancer cells. The overexpres-
sion of Glut1 in human cancers is known to be related to a variety of histopathological param-
eters, including histological grade, proliferation rate, and lymphatic invasion. The principal ob-
jective of this study was to evaluate Glut1 expression in the spectrum of pulmonary neuroen-
docrine (NE) tumors including typical carcinoid tumor (TC), atypical carcinoid tumor (AC), large
cell neuroendocrine carcinoma (LCNEC), and small cell carcinoma (SCC), and to character-
ize the relationship between Glut1 expression and the histologic grade of NE tumors. Meth-
ods : 19 TC, 7 AC, 13 LCNEC, and 6 SCC patients were included in this study. The percent-
ages of Glut1-positive tumor cells in these patients were determined. For statistical analysis,
Glut1 expression was subdivided into a Glut1-low expression group (0 -30%) and a Glut1-
high expression group (31-90%). Results : In our subgroup analyses, the histological grade
of pulmonary neuroendocrine (NE) tumors was significantly correlated with Glut1 expression;
TC (n=19, 3.6±4.2%), AC (n=7, 20.0±4.9%), LCNEC (n=13, 60.0±21.1%), and SCC (n=
6, 74.2±16.9%). Glut1-high expression was significantly associated with high-grade NE tumors
such as LCNEC and SCC (n=19, 62.6±21.0%) (p=0.000). Conclusions : The results of this
study appear to indicate that Glut1 overexpression is a consistent feature of high-grade NE
lung tumors.
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In the recent revision of the 2004 WHO classification of lung
and pleural tumors,1 pulmonary neuroendocrine (NE) tumors
include typical carcinoid (TC), a low-grade malignancy; atypi-
cal carcinoid (AC), an intermediate -grade malignancy; and large
cell neuroendocrine carcinoma (LCNEC) and small cell carcino-
ma (SCC), both of which are high-grade malignancies. The prog-
nosis and biologic behaviors of NE tumors deteriorate accord-
ing to their histologic grade.2 Treatment depends heavily on the
histologic features, which reflect differences in clinical behavior
and prognosis.
Glut1 is a facilitative glucose transporter transmembrane pro-
tein, which is physiologically expressed and immunohistochem-
ically detectable in red blood cell membranes,3 brain capillary
endothelium (the blood brain barrier),4 and the perineurium of
the peripheral nerve. It is also expressed in the placenta,5 basal
cells of the benign squamous epithelium,6 reactive epidermal
cells, and many epithelial neoplasms. It plays a mediating role
in cellular glucose uptake. Malignant cells evidence increased
glucose uptake and utilization when compared to their benign/
normal counterparts in vitro and in vitro.7 Several studies have
reported an association between Glut1 expression and neoplas-
tic progression in various human cancers, including ovarian ep-
ithelial malignancy,8 colorectal adenocarcinoma,9 adenocarcino-
ma arising in Barrett’s metaplasia of the esophagus,10 endome-
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trial adenocarcinomas,11 human head and neck tumors,12 breast
cancer13 and renal cell carcinomas.14
Song et al.15 previously reported that Glut1 expression in pul-
monary NE tumors was correlated with 18F-fluorodeoxyglucose
(FDG) uptake on positron emission tomography (PET). How-
ever, the majority of the specimens included in the previous study
were obtained from small biopsy samples, and the correlation of
Glut1 expression with histologic grade has yet to be fully eval-
uated. Thus, we enrolled only surgically resected NE tumors and




Forty-five patients with NE lung tumors (35 men, 10 women:
age range 24-80 year; mean 58 year) who underwent curative
surgical resection at the Seoul National University Hospital and
Bundang Hospital between 1995 and 2006 were enrolled in this
study. H&E-stained slides of each tumor were reviewed for sub-
type in the NE lung tumors, and the tumors were then reclas-
sified in accordance with the 2004 WHO classification system.1
The pathologic diagnoses were as follows: TC (n=19), AC (n=7),
LCNEC (n=13), and SCC (n=6).
Immunohistochemistry
Formalin-fixed, paraffin-embedded 4 μm tissue sections were
immunostained with rabbit anti-Glut1 polyclonal antibody for
Glut1 (1:50, Neomarkers, Fremont, CA, USA), via a previously
described procedure.15,16 Adjacent sections incubated with rab-
bit IgG were employed as negative controls. Red blood cells pre-
sent in each section were used as positive controls for Glut1.
Glut1 expression was considered positive only if distinct mem-
brane staining was detected. Glut1 expression was presented as
%Glut1 expression, and the percentages of immunostaining-
positive cells were measured by counting tumor cell numbers,
i.e. the number of distinctly stained membranes per 1,000 tumor
Fig. 1. Immunohistochemical staining of Glut1 expression in NE tumors of the lung: TC (A), AC (B) , LCNEC (C) and SCC (D). Glut1 was
expressed in the membrane of tumor cells (×400).
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cells in the most representative region at 400X magnification.
Statistical analysis
The analyses in this study were conducted using the SPSS soft-
ware package for Windows, version 12.0. The relationship be-
tween %Glut1 expression and histological grade was assessed
via Pearson Chi-Square analysis. p-values <0.05 were considered
statistically significant.
RESULTS
The Glut1 staining was detected primarily in the membra-
nous pattern (Fig. 1). A case of TC showed diffuse intracytoplas-
mic staining without a membranous pattern, and was considered
0%. The proportion of Glut1 expression in all NE tumors var-
ied in accordance with histologic type. The %Glut1 expression
of NE lung tumors ranged between 0 and 90% (mean 30.8±
31.2%), and the means of %Glut1 expressions of TC, AC, LC-
NEC, and SCC were 3.6±4.2%, 20.0±4.9%, 60.0±21.1%,
and 74.2±16.9%, respectively (Fig. 2).
For statistical analysis, the cases were subdivided into a Glut1-
low expression group (0-30%) and a Glut1-high expression gro-
up (30-90%). NE lung tumors were also subdivided into low-
to-intermediate grade and high-grade. Glut1-high expression
was significantly associated with high-grade NE lung tumors
(p=0.000) (Table 1).
DISCUSSION
Glut1, the human erythrocyte glucose transporter, is a mem-
ber of an expanding family of transmembrane proteins known
as the facilitative glucose transporters, a family which currently
comprises 12 members.3 Under physiological conditions, Glut1
is expressed in a limited number of organs, including the brain,
placenta, breast, and kidney, in addition to RBC.17 Recently,
Glut1 has become the focus of considerable attention with FDG-
PET in tumor biology.15,16,18,19 Glut1 expression has been noted
in a broad variety of human tumors, including ovarian epithe-
lial malignancy,8 adenocarcinomas of endometrial11 and colonic
origin,9 invasive and in situ squamous carcinomas of the skin,20
head and neck squamous carcinomas,12 papillary thyroid carci-
noma,21 renal cell carcinoma,14 esophageal Barrett-associated ad-
enocarcinoma,10 nonsmall cell lung carcinoma16,22-25 and breast
carcinomas.26 Additionally, Glut1 is associated with significant-
ly more aggressive tumor course, thus indicating that Glut1, a
highly efficient glucose transporter, may perform a role in main-
taining the high-energy requirements of aggressive carcinomas.
Thus, Glut1 expression has been identified as a possible new di-
agnostic and prognostic marker in certain human cancers.8,9,11,22,26
In this study, we assessed Glut1 expression in NE lung tumors
via immunohistochemistry. We determined that high Glut1
expression levels in NE lung tumors were associated with high-
grade histology. This is why the criteria for NE lung tumor his-
tologic grade include mitosis and tumor proliferative activity.
Glut1 expression has been associated with histologic subtype,
lymphatic invasion, lymph node metastasis, Ki-67 proliferative
index, and so forth.9,16,19 However, the principal criterion for the
histologic grade of squamous cell carcinoma is morphological
squamous differentiation (well, moderate, poorly differentiat-
ed), such that high Glut1 expression is unrelated to high-grade
histology.16,23-25 Low expression of Glut1 staining in TC, in con-
trast to the middling levels of expression seen in intermediate
grade AC tumors and the high expression in high-grade NE
tumors such as LCNEC and SCC, is consistent with findings in
several other anatomic sites.8,9,11
Fig. 2. Glut1 immunoreactivity in histologic types of neuroendocrine











TC AC LCNEC SCC
Glut1 (%)
Glut1-low 26 2 28
Glut1-high 0 17 17
p-value <0.001 <0.001
Mean of %Glut1 (%) 7.5±7.7 62.6±21.0 30.8±31.2
TC, typical carcinoid; AC, atypical carcinoid; LCNEC, large cell neuroen-
docrine carcinoma; SCC, small cell lung carcinoma.
Low to interme- 
High grade
diate grade
TC and LCNEC and
AC (n=26) SCC (n=19)
Total
(n=45)
Table 1. Correlations between low or high Glut1 expression and
histologic grade of neuroendocrine tumors of the lung
According to Song et al.,15 Glut1 expression in NE lung tu-
mors is correlated positively with FDG uptake. The authors con-
sidered all kinds of Glut1 expression patterns, i.e., intracytoplas-
mic, membranous or mixed intracytoplasmic and membranous
patterns as a positive reaction, in contrast to other papers con-
cerning Glut1 immunohistochemical staining. In this paper, a
very interesting TC case was reported with high FDG uptake
and diffuse intracytoplasmic Glut1 expression, rather than a
membranous pattern. As Glut1 is a transmembrane protein,
when evaluating Glut1 expression, the membranous pattern
should be considered, as was the case in other papers.8,11,16 We
concluded that a membranous pattern is the only reliable crite-
rion for true expression of Glut1 as a transporter protein, and
regarded the Glut1 expression of TC as 0%. In that case, the
patient had been regularly attending a hospital for treatment of
Cushing’s syndrome, and he was already aware of the existence of
a solitary mass in the lung, and also that the size of the mass
had remained constant for 20 years. The clinicians in this case
suspected that the solitary mass was a malignancy, based on the
high uptake noted upon FDG-PET examination (max SUV
29.5). After surgery, it was histologically confirmed as a TC and
the patient’s condition evidenced benign biologic behavior, with-
out recurrence or metastasis for 4 years. This case may represent
an extreme example of TC. The diffuse intracytoplasmic pattern
of Glut1 expression evidenced by the TC might be explained as
follows: 1) anti-Glut1 antibody was stained nonspecifically in
the intracytoplasmic NE secretory granules, 2) glucose was not
catalytically hydrolyzed by glucose-6-phosphatase, and intracy-
toplasmic accumulation occurred via some abnormal mechanism.
Thus, we should not oversimplify the case simply because the
TC evidenced abundant expression of Glut 1. Further large-scale
studies are recommended to generate more information regard-
ing Glut1 metabolism in NE lung tumors.
In summary, we determined that Glut1 overexpression is a
consistent feature of high-grade NE lung tumors. Although the
biological function of Glut1 in NE lung tumors remains to be
thoroughly explained, Glut1 expression should be considered a
possible source of new prognostic information about histologic
grade.
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